Presented here are few of the products which Vertex Product Development has designed, engineered and developed from conception to production for the Consumer, Commercial, Industrial and Medical industries.
Presented here are few of the products which Vertex Product Development has designed, engineered and developed from conception to production for the Consumer, Commercial, Industrial and Medical industries.
Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/
With Arizona facing its share of tragedies lately – economically, politically and most recently the wildfires which have impacted thousands of residents – the community has found comfort in rallying together to celebrate the grand opening of the new Phoenix Children’s Hospital. The campus of Arizona’s only hospital 100 percent for children grew from 345 licensed beds to 465, and will ultimately house 626 licensed beds at full build-out, expected in 2013.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phoenixchildrenshospital/50358/
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that its Selenia Dimensions 2D/3D mammography system won a gold Medical Design Excellence Award (MDEA) at the Medical Design and Manufacturing East 2011 Conference and Exposition.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hologic/50095/
In a bold move to address the healthcare affordability crisis, Blue Shield of California Chairman & CEO Bruce Bodaken announced a pledge today that Blue Shield will limit its annual net income to no more than 2 percent of revenue. This commitment will apply retroactively to income earned in 2010, when Blue Shield’s net income exceeded the 2 percent target by $180 million. That amount will go back to Blue Shield’s customers and the community.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bsc/50440/
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Could migraine patients be doing more to get the most out of their medical visits? According to a new national survey released by the National Headache Foundation (NHF) and GlaxoSmithKline, the answer is yes. For the nearly 30 million migraine sufferers in the U.S., including six million treating with prescription medication, these survey results may have important implications.
The survey, conducted online in November 2010 by Harris Interactive, included 1,218 diagnosed migraine patients taking prescription medications for their migraine attacks as well as 533 physicians who treat between five and 10 migraine patients per week. The findings revealed disparities between what patients and physicians each reported typically discussing during office visits.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/glaxosmithkline/48596/
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, has announced the first nine U.S. cities for a series of evening events to introduce clinicians to the Selenia Dimensions 2D/3D breast tomosynthesis system and gain hands-on experience with this new technology.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hologic/50094/
Medical researchers are making unprecedented progress into understanding why women suffer disproportionately from a number of diseases. Those insights are providing information to help develop medicines to attack diseases such as osteoporosis, multiple sclerosis, depression, rheumatoid arthritis and age-related macular degeneration, all of which affect more women than men.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/50270/
According to a new report, How Can We Avoid a Stroke Crisis in the Asia-Pacific Region?, urgent coordinated action is needed to avoid millions of preventable strokes, which leave many patients who have atrial fibrillation (AF) both mentally and physically disabled, or dead, every year.
The report, launched today during the 18th Asian Pacific Congress of Cardiology (APCC) by Action for Stroke Prevention, a group of health experts from across the globe, proposes urgent measures to prevent stroke in Asia-Pacific patients with AF, the most common, sustained abnormal heart rhythm and a major cause of stroke. The report’s recommendations are endorsed by 32 leading Asia-Pacific and other global medical societies and patient organizations, reinforcing and recognizing the need for a call to action.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/strikeoutstroke/48909/
